版本:
中国

BRIEF-Immunocellular Therapeutics reports updated immune monitoring data from ICT-107 phase 2

Nov 21 Immunocellular Therapeutics Ltd

* Immunocellular Therapeutics reports updated immune monitoring data from ICT-107 phase 2 trial in newly diagnosed glioblastoma at the society for neuro-oncology annual meeting 2016

* Immunocellular therapeutics ltd - Data from phase 2 trial indicated a survival advantage in ICT-107 treated group compared to control group

* Immunocellular therapeutics - In current ongoing phase 3 registration trial of ICT-107, co plans to perform immuno-monitoring to support trial

* Immunocellular Therapeutics - Phase 2 trial data also showed association between immune response, survival, especially in HLA-A2 positive patients

* Immunocellular Therapeutics- Updated immune response data from phase 2 trial showed ICT-107 resulted in development of measurable anti-tumor T cell response

* Immunocellular Therapeutics - Updated immune response data showed ICT-107 resulted in development of measurable anti-tumor T cell response in some patients Source text for Eikon: Further company coverage:

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐